MGRC

Executive Director Dato’ Alvin Joseph Nesakumar was appointed as Non-Independent Non- Executive Director of the Company on 10 June 2020. Subsequently, he was re-designated as Executive Director on 21 August 2020.

Dato’ Alvin began his career in Sales and Marketing for electronic components at Panasonic Electronic Devices Malaysia Sdn Bhd (previously known as Matsushita). During his 17-plus years there, he was one of the senior members of the Sales and Marketing division covering the global sales of Panasonic electronic components in Hong Kong and China in the late 1990s, and later the Americas, Europe and Asia Pacific regions.

In the early 2000s, Dato’ Alvin ventured into the pharmaceutical industry. He connected with a group of investors and professionals and they pioneered the concept of ‘compounding pharmacy’ and personalised medicine. He has since expanded his reach into research laboratory services and stem cells. In this, he co-founded Stem Cell First to market the application of stem cells for medical treatment and regenerative medicine.

He aspires to delve further into early detection and preventive medicine by combining technology and medicine with the latest technology from strategic partners globally to reshape the local health industry.

Dato’ Alvin completed his Cambridge A-Levels at KDU College in 1988, and his Sijil Tinggi Persekolahan Malaysia (STPM) from Sekolah Kebangsaan Sulaiman, Bentong, Pahang in 1987.
Dato’ Alvin has not attended any Board of Directors’ Meeting as there was no Board of Directors’ Meeting held since his appointment as Director on 10 June 2020 in the financial year ended 30 June 2020.

Other than as disclosed, Dato’ Alvin does not have any family relationship with any directors and/or major shareholders of the Company and has no conflict of interest with the Company. He has not been convicted of any offences within the last 5 years, other than the traffic offences, if any, and public sanction or penalty imposed by the relevant regulatory bodies, during the financial year ended 30 June 2021.

Chief Executive Officer Encik Sasha Nordin was appointed as the Chief Executive Officer (“CEO”) on 23 September 2020. Prior to his appointment as CEO of the Company, he was the Chief Operating Officer of the Company since 1 February 2014.

Prior to joining the Company, he was employed at Neuramatix Sdn Bhd, the previous ultimate holding company of Malaysian Genomics Resource Centre Berhad (“MGRC”), for a period of 12 years. In 2016, he was awarded a Master in Business Administration with Distinction from the University of Strathclyde, Glasgow.

Encik Sasha has over 21 years’ experience in business development, project planning and management, product development, and strategic marketing. He contributes to the growth needs of the Company. This has included the sourcing of grant and public funds for research and development, maintaining communications with strategic stakeholders, and contributing to strategic planning.

Encik Sasha does not have any directorships in other public companies and public listed companies. He does not have any family relationship with any directors and/or major shareholders of the Company and has no conflict of interest with the Company.

He has not been convicted of any offences within the last 5 years, other than traffic offences, if any, and public sanction or penalty imposed by the relevant regulatory bodies, during the financial year ended 30 June 2021.

Financial Controller Ms Teoh Ai Ling was appointed as the Financial Controller of the Company on 30 November 2021. She is a Fellow of the Association of Chartered Certified Accountants (FCCA).

Prior to joining the Company, Ms Teoh started her career as an external auditor for private and public listed companies in various industries, such as trading, manufacturing, property development and construction, oil and gas, pharmaceutical and hospitality. She later progressed to the position of Financial Controller for several public listed companies, overlooking the financial reporting and operations of the Group of Companies.

Ms Teoh does not have any family relationship with any directors and/or major shareholders of the Company, and has no conflict of interest with the Company.

She has not been convicted of any offences within the last 5 years, other than the traffic offences, if any, and public sanction or penalty imposed by the relevant regulatory bodies, during the financial year ended 30 June2021.